Media Center

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act):

"H.R. 965, the 'Creating and Restoring Equal Access to Equivalent Samples Act of 2019,' or the 'CREATES Act,' is bipartisan legislation that would substantially lower drug prices by making it easier for generic pharmaceutical companies to obtain drug samples from branded companies, which they require in order to perform testing necessary to enter the market.

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act:

"H.R. 2375, the 'Preserve Access to Affordable Generics and Biosimilars Act' is one of a series of bipartisan measures that we are considering today to address the critical need to lower the soaring cost of prescription drugs, which is jeopardizing the health and well-being of millions of Americans.

In a victory for Members of Congress, Judge Emmet Sullivan of the U.S. District Court for the District of Columbia has now denied, in full, President Trump's motion to dismiss the challenge brought by roughly 200 Members of the Senate and House of Representatives, to hold him accountable to the Constitution's Foreign Emoluments Clause. On learning this news, the lead plaintiffs and their counsel issued the following statement:

Today, House Judiciary Committee Chairman Jerrold Nadler released a statement in response to reports that Special Counsel Robert Mueller wrote to Attorney General William Barr last month to object to the Attorney General's summary of his report:

Washington, D.C. - Reps. Jerrold Nadler (D-N.Y.), Chairman of the House Judiciary Committee and Doug Collins (R-Ga.), Ranking Member of the House Judiciary Committee, today introduced the Prescription Pricing for the People Act of 2019. The legislation requires the Federal Trade Commission (FTC) to study pharmacy benefits managers (PBMs) and how their actions are affecting patients and local pharmacies. The legislation will be marked up in the House Judiciary Committee on April 30, 2019.

On April 30, 2019 at 2pm, the House Judiciary Committee will consider four bills to address prescription drug pricing, including H.R. 965, the CREATES Act; H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 2374, the Stop STALLING Act; and H.R. 2376, the Prescription Pricing for the People Act of 2019.

Date: April 30, 2019

Time: 2:00 p.m.

Location: 2141 Rayburn House Office Building

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) and Ranking Member Doug Collins (R-GA) introduced H.R. 2375, the bipartisan Preserve Access to Affordable Generics and Biosimilars Act. This legislation strengthens the Federal Trade Commission's (FTC) ability to challenge settlement agreements between large brand drug companies and generic drug companies in court, which will help lower prescription drug prices for Americans. The legislation will be marked up in the House Judiciary Committee on April 30, 2019.